KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Biomarin Pharmaceutical (BMRN) over the last 13 years, with Q3 2025 value amounting to $196.9 million.

  • Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) fell 12.88% to $196.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.9 million, marking a year-over-year decrease of 12.88%. This contributed to the annual value of $196.7 million for FY2024, which is 266.87% up from last year.
  • Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) amounted to $196.9 million in Q3 2025, which was down 12.88% from $197.1 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Shares Outstanding (Diluted Average)'s 5-year high stood at $200.5 million during Q2 2024, with a 5-year trough of $182.9 million in Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $194.9 million (2022), whereas its average is $192.8 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first plummeted by 731.51% in 2021, then surged by 570.66% in 2022.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) stood at $182.9 million in 2021, then rose by 3.34% to $189.0 million in 2022, then grew by 1.39% to $191.6 million in 2023, then increased by 2.67% to $196.7 million in 2024, then rose by 0.09% to $196.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $196.9 million in Q3 2025, compared to $197.1 million in Q2 2025 and $196.5 million in Q1 2025.